Alexis Ndjolo

Alexis Ndjolo

Auto-generated profile, based on publicly available information

Alexis Ndjolo

Centre International de Référence Chantal Biya

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 January 2023 in African Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
RKRachel S. Kamgaing
Rachel S. Kamgaing
YBYagai Bouba
Yagai Bouba
SSSamuel Martin Sosso
Samuel Martin Sosso
JGJeremiah E. Gabisa
Jeremiah E. Gabisa
ANAubin Nanfack
Aubin Nanfack
ANAlexis Ndjolo
Alexis Ndjolo
Introduction: Determining the HIV status of some individuals remains challenging due to multidimensional factors such as flaws in diagnostic systems, technological challenges, and viral diversity. This report pinpoints challenges faced by the HIV testing system in Cameroon. Case presentation: A 53-year-old male received a positive HIV result by a rapid testing algorithm in July 2016. Not convinced of his HIV status, he requested additional tests. In February 2017, he received a positive result using ImmunoComb® II HIV 1 & 2 BiSpot and Roche cobas electrochemiluminescence assays. A sample sent to France in April 2017 was positive on the Bio-Rad GenScreen™ HIV 1/2, but serotyping was indeterminate, and viral load was < 20 copies/mL. The Roche electrochemiluminescence immunoassay and INNO-LIA HIV I/II Score were negative for samples collected in 2018. A sample collected in July 2019 and tested with VIDAS® HIV Duo Ultra enzyme-linked fluorescent assay and Geenius™ HIV 1/2 Confirmatory Assay was positive, but negative with Western blot; CD4 count was 1380 cells/mm3 and HIV proviral DNA tested in France was ‘target-not-detected’. Some rapid tests were still positive in 2020 and 2021. Serotyping remained indeterminate, and viral load was ‘target-not-detected’. There were no self-reported exposure to HIV risk factors, and his wife was HIV-seronegative. Management and outcome: Given that the patient remained asymptomatic with no evidence of viral replication, no antiretroviral therapy was initiated. Conclusion: This case highlights the struggles faced by some individuals in confirming their HIV status and the need to update existing technologies and develop an algorithm for managing exceptional cases.

1 January 2025 in Journal of Public Health in Africa
Verified
Journal Article
Open access
PDF file
PDPatrice Djataou
Patrice Djataou
MNMarceline D. Ngounoue
Marceline D. Ngounoue
GNGeorges Nguefack-Tsague
Georges Nguefack-Tsague
JAJean de Dieu Anoubissi
Jean de Dieu Anoubissi
JKJoséphine J.K. Kadji
Joséphine J.K. Kadji
CNCéline Nguefeu Nkenfou
Céline Nguefeu Nkenfou
Background: Human immunodeficiency viruses (HIV) and acquired immunodeficiency syndrome (AIDS) remain a global public health problem. Other sexually transmitted infections (STIs) are aggravating factors. Aim: This study aimed to assess the prevalence and identify new cases of HIV and STIs, as well as their associated risk factors. Setting: Political insecurity in the northern regions of Cameroon has led to population displacement, weakening an already fragile health system. Methods: A cohort of 684 consenting participants from the north and far north were enrolled in 2021 and followed up in 2022. Socio-demographic variables and risk behaviours were collected. Anti-HIV Ab, hepatitis B surface antigen, Treponema pallidum haemagglutination tests were performed. The data were analysed using Epi Info 7.5.2. The associations between variables were evaluated using the Chi-square test with a 95% confidence interval. Results: The new cases of HIV rate and overall prevalence were 1.63% (95% confidence interval [CI]: 0.83% – 2.41%) and 3.8% (95% CI: 2.01% – 3.97%), respectively. New HIV cases increased from 0.27% (2017, Demographic and Health Survey [DHS]) to 1.63%. The prevalence of syphilis and hepatitis B was 1.03% (95% CI: 0.98% – 1.09%) and 4.56% (95% CI: 4.51% – 4.66%), respectively. Factors associated with HIV included religion (p = 0.027), unprotected sex (p = 0.006), sex with a sex worker (p = 0.00009), and co-infection with syphilis and hepatitis B (p = 0.033). New HIV infections may also be associated with population displacement. Conclusion: HIV infection, syphilis and hepatitis B are on the rise in the Northern Cameroon. Contribution: Future HIV prevention strategies should consider population displacement and HIV-associated infections such as hepatitis B and syphilis in order to secure achievements in HIV programme and further curb the burden of these infections in the country.

9 March 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
CTCarine Tadenfok
Carine Tadenfok
JFJoseph Fokam
Joseph Fokam
ESEzechiel Ngoufack Jagni Semengue
Ezechiel Ngoufack Jagni Semengue
LMLeonella Mossiang
Leonella Mossiang
SOSteve Oyie
Steve Oyie
CNCéline Nguefeu Nkenfou
Céline Nguefeu Nkenfou
HIV treatment has significantly improved with the introduction of potent antiretroviral therapy (ART), particularly dolutegravir (DTG)-based regimens. With

1 January 2025 in Journal of Public Health in Africa
Verified
Journal Article
Open access
PDF file
JFJoseph Fokam
Joseph Fokam
CACyrille Alain Abega Abega
Cyrille Alain Abega Abega
ESEzechiel Ngoufack Jagni Semengue
Ezechiel Ngoufack Jagni Semengue
AAAissatou Abba
Aissatou Abba
DTDésiré Takou
Désiré Takou
ANAlexis Ndjolo
Alexis Ndjolo
Optimised supplies management for an efficient response in a context of a pandemic in Cameroon. Background: Response strategy against COVID-19 relies on adequate materials and consumables supply. Aim: As a national reference COVID-19 laboratory in Cameroon, the Chantal BIYA International Reference Center (CIRCB) has evaluated the consumption of materials and consumables supply for PCR, variant screening and sequencing, in view of better prediction of the needs. Setting: Chantal Biya International Reference Centre for research on human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) prevention and management (CIRCB), Yaoundé-Cameroon. Methods: This was a descriptive cross-sectional study conducted between August 2021 and July 2022 which focused on stock supply evaluation through analysis of data from services performed at CIRCB, Cameroon. The weighted averages method was used in statistics. Results: Overall, 31 453 samples were received, 37 008 extractions and 37 248 PCRs were performed for COVID-19 diagnosis, representing an average monthly consumption of 3084 extractions and 3104 PCRs for ~2621 samples/month (~1.17 extractions/sample and ~1.18 PCRs/sample). Of the 2238 (7.1%) positive cases diagnosed, 265 were processed for variants’ screening and 200 to sequencing due to their high cycle threshold (CT < 25). In screening, 288 tests were used, i.e. 1.08 tests/sample. For sequencing, 279 tests were used, i.e. 1.39 tests/sample. Conclusion: The estimates obtained reveal a precise quantification of the supplies used for diagnosis, variant screening and sequencing during a season of high COVID-19 epidemics at CIRCB-Cameroon. Contribution: Adequate implementation of this logistical strategy would optimize supply management and help to save associated costs while ensuring effective genomic surveillance or response when faced with any public health incident in Cameroon.

1 January 2026 in Journal of Public Health in Africa
Verified
Journal Article
Open access
PDF file
MTMichel Carlos TOMMO TCHOUAKET
Michel Carlos TOMMO TCHOUAKET
JFJoseph Fokam
Joseph Fokam
ESEzechiel Ngoufack Jagni Semengue
Ezechiel Ngoufack Jagni Semengue
YBYagai Bouba
Yagai Bouba
CACollins Chenwi Ambe
Collins Chenwi Ambe
ANAlexis Ndjolo
Alexis Ndjolo
Background: Nasopharyngeal swabs (NASO) cause discomfort for patients, which can discourage them from getting tested for COVID-19 and limit case detection. It is therefore necessary to consider an alternative, more comfortable swab. Aim: Evaluated the concordance between nasopharyngeal and oropharyngeal sampling for COVID-19 diagnosis in the Cameroonian context. Setting: This study was carried out at “Chantal Biya” International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB) in Yaoundé, Cameroon. Methods: A comparative study was conducted in April 2021 among consenting participants tested for COVID-19 at “Chantal Biya” International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB) in Yaoundé, Cameroon. Sampling began with nasopharyngeal swabs, followed by oropharyngeal swabs, all taken by the same technician, and analysis was carried out using polymerase chain reaction (PCR) tests on the Abbott platform. Statistical analyses were performed using GraphPad version 6.0; p < 0.05 was considered statistically significant. Results: A total of 154 participants were enrolled (59.7% male, median age 38 years, interquartile range [IQR]: 30–49). Following PCR testing, the overall COVID-19 positivity rate was 36.36% (56/154), with 34.41% (n = 53/154) in nasopharyngeal versus 16.23% (n = 25/154) in oropharyngeal samples, p < 0.0002. The overall concordance rate was 78% (n = 120/154), with 39.28% positive concordance and 74.24% negative concordance (kappa = 0.441 [0.289–0.513]). According to severe acute respiratory syndrome coronavirus 2 viral load, the positive concordance was improved with high viral load (cycle threshold [CT]: ≤ 25): 61% (n = 11/18) versus 31% (n = 11/35) with low viral load (CT > 25), p = 0.037; odds ratio (OR) = 3.43. According to gender, the positive concordance was higher in men, 55% (n = 16/29), versus 25% (n = 6/24) in women, p = 0.021; OR = 0.27. Using nasopharyngeal swab as the gold standard, oropharyngeal swab had a sensitivity of 41.50% (n = 22/53), specificity 97.02% (n = 98/101), positive predictive value (PPV) 88% (n = 22/25) and negative predictive value (NPV) 76% (n = 98/129). Conclusion: Our evidence suggests a superiority effect of nasopharyngeal in detecting cases of COVID-19. However, the overall high PPV of oropharyngeal swab, and its improved performance with high viral load. Contribution: Therefore, in case of counter-indication to nasopharyngeal swabbing, oropharyngeal can be an acceptable alternative.

29 November 2022 in JMIR Research Protocols
Verified
Journal Article
Open access
ANAubin Nanfack
Aubin Nanfack
GAGeorgia Ambada
Georgia Ambada
JFJoseph Fokam
Joseph Fokam
AKAude Christelle Ka'e
Aude Christelle Ka'e
Nelson SonelaNelson Sonela
Nelson Sonela
ANAlexis Ndjolo
Alexis Ndjolo
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Antiretroviral therapy (ART) can bring HIV-1 in blood plasma to level undetectable by standard tests and allow a near-normal life expectancy for HIV-infected individuals. Unfortunately, ART is not curative and must be taken for life, as within a few weeks of treatment cessation, HIV viremia rebounds in most patients except for rare elite or post-treatment controllers of viremia. The primary source of this rebound is the highly stable reservoir of latent yet replication-competent HIV-1 proviruses integrated into the genomic DNA of resting memory CD4+ T cells. To achieve a cure for HIV, understanding the cell reservoir environment is of paramount importance. The size and nature of viral reservoir might vary per timing of therapy, therapeutic response, ART duration, and immune response. Mechanisms of reservoir maintenance generally depend on levels/type of immune recognition; in addition, dynamics of viral persistence are different between pediatric and adult populations. This difference could become more evident as these children grow toward adolescence, a stage during which suboptimal adherence is frequent, leading to viral rebound and archiving of resistant patterns. We plan to conduct a study with the aim to characterize HIV reservoirs and their variability per virological and immunological profiles in adolescents with HIV-1 non-B vertical infection receiving antiretroviral therapy. Methods: This study will involve adolescents with HIV-1 non-B vertical infection aged 10-19 years, have been on ART for at least 12 months, selected from an existing cohort in our research institution. Intravenous blood will be collected for immunological/virological profile including CD4/CD8 count, plasmatic viral load, immune activation/inflammatory markers, genotyping (protease and reverse transcriptase) and quantification of HIV-1 viral reservoirs. We will as well recruit an age matched group of HIV-negative adolescents as control for immunological profiling. Results: Data generated by this study will help in advancing knowledge on HIV reservoirs, in terms of size and genetic variability in adolescents living with HIV (ADLHIV). Such evidence will also help in understanding the effects of ART timing and duration on the size of reservoirs among ADLHIV, a unique population from whom findings generated will largely contribute in designing functional cure strategies.